Summary & Overview

Major Esophageal Disorders with CC: Inpatient Reimbursement Overview

DRG 369 addresses major non-malignant esophageal disorders with a Complication or Comorbidity that elevate clinical complexity and resource needs. This Diagnosis-Related Group matters for inpatient reimbursement because case assignment to this group versus non-Complication or Comorbidity or Major Complication or Comorbidity levels changes Medicare payment weights and hospital payment for esophageal care.

Major Esophageal DisordersDRG Major Esophageal Disorders with CCDRG 369Diagnosis-Related GroupInpatient ReimbursementMedicareGastroenterologyEsophageal SurgeryHospital CodingClinical Documentation

DRG 369 Overview

DRG 369 covers hospital admissions for major esophageal disorders with a Complication or Comorbidity that increase clinical complexity, including significant motility disorders, severe gastroesophageal reflux disease with complications, and other non-malignant structural esophageal conditions requiring inpatient care. This Diagnosis-Related Group groups cases where additional resources are used because of associated complications or comorbid conditions. It matters for Medicare payment because the presence of a Complication or Comorbidity shifts the case into a higher-weighted Diagnosis-Related Group relative to the non-Complication or Comorbidity category, affecting reimbursement and resource allocation for inpatient esophageal care. Reimbursement considerations focus on the principal diagnosis, secondary diagnoses that qualify as Complication or Comorbidity, and coded procedures performed during the stay.

Clinical Trials

Acute perioperative interventions study: randomized or prospective cohort trials testing intraoperative and immediate postoperative strategies to reduce morbidity and complications in patients undergoing major esophageal procedures (for example esophagectomy or extensive endoscopic interventions for advanced motility disorders). These studies enroll hospitalized adults with major esophageal pathology and focus on endpoints such as anastomotic leak rates, respiratory complications, blood loss, ICU length of stay, and 30-day readmission; they are relevant because complications drive long inpatient stays and high costs for this DRG. Providers need evidence on which perioperative protocols improve recovery and payers need data tying specific interventions to reduced resource utilization and episode cost.
Comparative effectiveness research of therapeutic approaches: observational comparative or pragmatic randomized trials comparing different definitive treatments for severe esophageal disease (for example open versus minimally invasive esophagectomy, different endoscopic ablative approaches, or medical versus surgical management of advanced motility disorders). These studies target patients with major structural or functional esophageal disorders complicated by comorbidities, assessing outcomes such as mortality, functional swallowing outcomes, complication-adjusted length of stay, and long-term need for reintervention. Results inform clinicians on which approaches provide the best balance of clinical benefit, complication risk, and hospitalization resource use, and inform payers about value across competing treatment pathways.
Post-discharge outcomes and care transitions research: prospective cohort or quality-improvement trials evaluating discharge planning, home health, nutrition support (including enteral feeding strategies), and readmission-prevention bundles in patients discharged after treatment for major esophageal disorders. These studies follow patients at high risk for malnutrition, aspiration, and recurrent hospitalization, measuring 30- and 90-day readmissions, nutritional status, outpatient complication rates, and total episode-of-care costs. Findings are directly relevant to hospitals and payers seeking to reduce readmissions and downstream costs while maintaining patient-centered outcomes for this high-risk DRG.

Related Codes

380-COMPLICATED-PEPTIC-ULCER-WITH-MCC

Complicated Peptic Ulcer with Major Complication or Comorbidity: Inpatient Reimbursement Overview

336-PERITONEAL-ADHESIOLYSIS-WITH-CC

Peritoneal Adhesiolysis with CC: Inpatient Reimbursement Overview

352-INGUINAL-AND-FEMORAL-HERNIA-PROCEDURES-WITHOUT-CC-MCC

Inguinal and Femoral Hernia Procedures without CC/MCC: Inpatient Reimbursement Overview

371-MAJOR-GASTROINTESTINAL-DISORDERS-AND-PERITONEAL-INFECTIONS-WITH-MCC

Major Gastrointestinal Disorders and Peritoneal Infections with MCC: Inpatient Reimbursement Overview

398-APPENDIX-PROCEDURES-WITH-CC

Appendix Procedures with CC: Inpatient Reimbursement Overview

344-MINOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

Minor Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

334-RECTAL-RESECTION-WITHOUT-CC-MCC

Rectal Resection without CC/MCC: Inpatient Reimbursement Overview

388-GASTROINTESTINAL-OBSTRUCTION-WITH-MCC

Gastrointestinal Obstruction with MCC: Inpatient Reimbursement Overview

347-ANAL-AND-STOMAL-PROCEDURES-WITH-MCC

Anal and Stomal Procedures with Major Complication or Comorbidity: Inpatient Reimbursement Overview

335-PERITONEAL-ADHESIOLYSIS-WITH-MCC

Peritoneal Adhesiolysis with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 57

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.